The Japanese pharmaceutical industry, a vital component of global innovation, faces a talent gap that resonates across multinational corporations. While Japan possesses a wealth of highly skilled professionals, a notable communication disparity impedes recruitment and career advancement, particularly in global…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Chuikyo Submits Recommendations for FY2014 Revision; Hospitals, Pharmacies with Low Settlement Rates to Face Fee Cuts of Up to 26％
February 12, 2014
-
ORGANIZATION Prof. Tsuchiya Slams Kowa’s Livalo Trademark Suit
February 10, 2014
-
ACADEMIA University of Tokyo Besieged with Medical, Pharma Research Woes, School’s Credibility at Stake
February 7, 2014
-
BUSINESS Kyorin Pushes Easy to Use Inhaler Flutiform, Aims for Higher Market Penetration
February 6, 2014
-
REGULATORY PMDA’s Next 5-Year Plan to Embrace New Generic Unit, Benchmarks for Review Time
February 5, 2014
-
BUSINESS Drug Wholesalers Laud Medical Fee Cuts to Fix Lengthy Haggling, Pharmacy Chains Vexed by Rule
February 4, 2014
-
BUSINESS Teijin Picks Another Pharma Maven for President
February 3, 2014
-
BUSINESS Sanofi Demands Payment of $416 Million from Novartis over Dissolved Equa Deal
January 31, 2014
-
BUSINESS Novartis Suspected of Drafting Letter of Consent for “Sign” Trial
January 30, 2014
-
BUSINESS Shionogi Influenza Campaign Causes Stir among Healthcare Professionals
January 29, 2014
-
ACADEMIA JCS’s 2013 Guidelines for Treatment of AF Recommend Dabigatran and Apixaban in Moderate-Risk Patients
January 29, 2014
-
REGULATORY MHLW Setting Out on Development of iPS Tech-Based Cardiotoxicity Evaluation
January 28, 2014
-
BUSINESS Ajinomoto to Downsize In-House Drug Discovery Research amid Slack Pharma Biz
January 27, 2014
-
BUSINESS Novartis Used Interim Report of “Sign” Trial in Tasigna Promotion, Set to Probe Its Involvement in Protocol Drafting
January 24, 2014
-
BUSINESS Novartis Adds LABA/LAMA Combination Ultibro to Lineup of Breezhaler Products for COPD Using the Same Inhaler
January 24, 2014
-
REGULATORY DPP-4 Inhibitors, Remicade to Face Market Expansion Re-Pricing in FY2014 Revision
January 23, 2014
-
BUSINESS Azilva Remains No.1 in December “Mind Share” Ranking in GP, HP Markets
January 22, 2014
-
BUSINESS Sales Reps Vied over Questionnaire Transfers in Tasigna Trial, Boss OK’ed Incentive Program: Novartis
January 21, 2014
-
BUSINESS Novartis Sales Reps Transferred Patient Questionnaires in Investigator-Led Trial
January 20, 2014
-
BUSINESS Japan’s First SGLT-2 Inhibitor Suglat Approved: Astellas
January 20, 2014
ページ
Following the launch of two new therapies since last year, Japan has seen fresh moves in drug development for amyotrophic…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…